CN114404561B - Protective agent for reducing vascular endothelial function damage - Google Patents
Protective agent for reducing vascular endothelial function damage Download PDFInfo
- Publication number
- CN114404561B CN114404561B CN202210267904.5A CN202210267904A CN114404561B CN 114404561 B CN114404561 B CN 114404561B CN 202210267904 A CN202210267904 A CN 202210267904A CN 114404561 B CN114404561 B CN 114404561B
- Authority
- CN
- China
- Prior art keywords
- barnacle
- barnacin
- peptide
- soft body
- cholesterol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/01—Hydrolysed proteins; Derivatives thereof
- A61K38/011—Hydrolysed proteins; Derivatives thereof from plants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
- C12P21/06—Preparation of peptides or proteins produced by the hydrolysis of a peptide bond, e.g. hydrolysate products
Abstract
The invention provides a protective agent for reducing vascular endothelial function damage, and belongs to the technical field of biomedicine. The effective component of the protective agent provided by the invention is barnacin, after the barnacin provided by the invention is used for treating human umbilical vein endothelial cells, the decrease of cell activity caused by cholesterol can be effectively reversed, and the increase of apoptosis promoting protein BAX caused by cholesterol and the decrease of apoptosis inhibiting protein BCL-2 caused by high cholesterol increase can be effectively reduced.
Description
Technical Field
The invention belongs to the technical field of biomedicine, and particularly relates to a protective agent for reducing functional damage of vascular endothelium.
Background
Atherosclerosis is a common vascular disorder in men over 40 years of age and postmenopausal women, and is the major pathological basis of cardiovascular and cerebrovascular disease. Current research has found that pathological progression in atherosclerotic patients often begins with vascular endothelial cell damage and lipid metabolism disorders. The vascular endothelium is an endothelial cell layer that is associated with the inner surface of the lumen of the vessel and, upon debridement, is a natural barrier between blood flow and the vessel wall. Functionally, the vascular endothelium regulates the structure and function of blood vessels, and plays an important role in maintaining various physiological and pathological functions in the body.
The vascular endothelial cells are a layer of mononuclear cells which are covered on the intima of a blood vessel and used for separating blood, vessel walls and various tissues and forming a continuous and smooth inner wall of the blood vessel. It is a key physical barrier for many cells, and endothelial cell damage can lead to endothelial dysfunction, leading to the development of atherosclerotic conditions, and thus, effective reduction of endothelial cell damage would be helpful in the treatment of atherosclerotic patients.
Disclosure of Invention
The invention aims to provide a protective agent capable of effectively reducing the functional damage of vascular endothelium.
In order to realize the purpose, the invention provides the following technical scheme:
the invention provides application of barnacle peptide in preparing a protective agent for reducing vascular endothelial injury, which is characterized in that the barnacle peptide is prepared from barnacle soft body parts, and the preparation method for preparing the barnacle peptide per 100g of the barnacle soft body parts comprises the following steps:
(1) Grinding 100g of barnacle soft body part into powder in a grinder added with liquid nitrogen;
(2) Adding 500ml of distilled water, mixing uniformly, adjusting the pH value to 6-7, adding 10g of papain, and hydrolyzing at 55-65 ℃ for 4-6h;
(3) After hydrolysis, heating in water bath at 90-95 ℃ for 20-30 minutes, centrifuging and collecting supernatant to obtain barnacle enzymatic hydrolysate;
(4) Filtering the barnacle enzymatic hydrolysate by using an ultrafiltration membrane of 5KDa, and collecting filtrate to obtain a barnacle peptide extracting solution;
(5) And (3) carrying out freeze drying on the barnacle peptide extracting solution to obtain the barnacle peptide.
Preferably, the protective agent can reduce cholesterol-induced decline in viability of human umbilical vein endothelial cells.
Preferably, the protective agent can reduce cholesterol-induced increased apoptosis in human umbilical vein endothelial cells.
The invention further provides an application of the barnacle peptide in preparing a biological agent for improving the reduction of the activity of human umbilical vein endothelial cells caused by cholesterol, wherein the barnacle peptide is prepared from barnacle soft body parts, and the preparation method for preparing the barnacle peptide per 100g of the barnacle soft body parts comprises the following steps:
(1) Grinding 100g of barnacle soft body part into powder in a grinder added with liquid nitrogen;
(2) Adding 500ml of distilled water, mixing, adjusting pH to 6-7, adding 10g of papain, and hydrolyzing at 55-65 deg.C for 4-6h;
(3) After hydrolysis, heating in water bath at 90-95 ℃ for 20-30 minutes, centrifuging and collecting supernatant to obtain barnacle enzymatic hydrolysate;
(4) Filtering the barnacle enzymatic hydrolysate by using a 5KDa ultrafiltration membrane, and collecting filtrate to obtain a barnacle peptide extracting solution;
(5) And (3) carrying out freeze drying on the barnacle peptide extracting solution to obtain the barnacle peptide.
Secondly, the invention provides an application of barnacle peptide in preparing a biological agent for improving the increase of the apoptosis of human umbilical vein endothelial cells caused by cholesterol, wherein the barnacle peptide is prepared from barnacle soft body parts, and the preparation method for preparing the barnacle peptide per 100g of the barnacle soft body parts comprises the following steps:
(1) Grinding 100g of barnacle soft body part into powder in a grinder added with liquid nitrogen;
(2) Adding 500ml of distilled water, mixing uniformly, adjusting the pH value to 6-7, adding 10g of papain, and hydrolyzing at 55-65 ℃ for 4-6h;
(3) After hydrolysis, heating in water bath at 90-95 ℃ for 20-30 minutes, centrifuging and collecting supernatant to obtain barnacle enzymatic hydrolysate;
(4) Filtering the barnacle enzymatic hydrolysate by using a 5KDa ultrafiltration membrane, and collecting filtrate to obtain a barnacle peptide extracting solution;
(5) And (3) carrying out freeze drying on the barnacle peptide extracting solution to obtain the barnacle peptide.
The invention further provides an application of the barnacle peptide in preparing a biological agent for reducing the increase of the expression of human umbilical vein endothelial cell apoptosis-promoting protein BAX protein caused by cholesterol, which is characterized in that the barnacle peptide is prepared from barnacle soft body parts, and the preparation method for preparing the barnacle peptide from every 100g of the barnacle soft body parts comprises the following steps:
(1) Grinding 100g of barnacle soft body part into powder in a grinder added with liquid nitrogen;
(2) Adding 500ml of distilled water, mixing uniformly, adjusting the pH value to 6-7, adding 10g of papain, and hydrolyzing at 55-65 ℃ for 4-6h;
(3) After the hydrolysis is finished, heating in water bath at 90-95 ℃ for 20-30 minutes, centrifuging and collecting supernatant to obtain barnacle enzymatic hydrolysate;
(4) Filtering the barnacle enzymatic hydrolysate by using a 5KDa ultrafiltration membrane, and collecting filtrate to obtain a barnacle peptide extracting solution;
(5) And (3) carrying out freeze drying on the barnacle peptide extracting solution to obtain the barnacle peptide.
The invention further provides an application of the barnacle peptide in preparing a biological agent for improving the reduction of the expression of human umbilical vein endothelial cell apoptosis inhibiting protein BCL-2 protein caused by cholesterol, which is characterized in that the barnacle peptide is prepared from barnacle soft parts, and the preparation method for preparing the barnacle peptide from the barnacle soft parts per 100g comprises the following steps:
(1) Grinding 100g of barnacle soft body part into powder in a grinder added with liquid nitrogen;
(2) Adding 500ml of distilled water, mixing uniformly, adjusting the pH value to 6-7, adding 10g of papain, and hydrolyzing at 55-65 ℃ for 4-6h;
(3) After hydrolysis, heating in water bath at 90-95 ℃ for 20-30 minutes, centrifuging and collecting supernatant to obtain barnacle enzymatic hydrolysate;
(4) Filtering the barnacle enzymatic hydrolysate by using a 5KDa ultrafiltration membrane, and collecting filtrate to obtain a barnacle peptide extracting solution;
(5) And (3) carrying out freeze drying on the barnacle peptide extracting solution to obtain the barnacle peptide.
In addition, the invention provides a protective agent for reducing vascular endothelial function damage, which is characterized in that the effective component of the protective agent is barnacin, the barnacin is prepared from barnacin soft body parts, and the preparation method for preparing the barnacin per 100g of the barnacin soft body parts comprises the following steps:
(1) Grinding 100g of barnacle soft body part into powder in a grinder added with liquid nitrogen;
(2) Adding 500ml of distilled water, mixing, adjusting pH to 6-7, adding 10g of papain, and hydrolyzing at 55-65 deg.C for 4-6h;
(3) After the hydrolysis is finished, heating in water bath at 90-95 ℃ for 20-30 minutes, centrifuging and collecting supernatant to obtain barnacle enzymatic hydrolysate;
(4) Filtering the barnacle enzymatic hydrolysate by using an ultrafiltration membrane of 5KDa, and collecting filtrate to obtain a barnacle peptide extracting solution;
(5) And (3) carrying out freeze drying on the barnacle peptide extracting solution to obtain the barnacle peptide.
The invention has the beneficial effects that:
the invention discovers that after the barnacin provided by the invention is used for treating human umbilical vein endothelial cells, the decrease of cell activity caused by cholesterol can be effectively reversed, the increase of apoptosis promoting protein BAX caused by cholesterol can be effectively reduced, and the decrease of apoptosis inhibiting protein BCL-2 caused by high cholesterol can be effectively reduced, so that vascular endothelial injury can be effectively realized, and the barnacin can be used for treating atherosclerosis caused by high-fat diet.
Drawings
FIG. 1 Effect of barnacin peptides on the cholesterol-induced decrease in cellular activity of HUVEC;
FIG. 2 Effect of barnacin on cholesterol-induced up-regulation of protein expression of the pro-apoptotic protein BAX and down-regulation of protein expression of the cytostatic protein BCL-2.
Detailed Description
In order to clearly illustrate the technical features of the present solution, the present solution is explained below by way of specific embodiments.
Example 1
(1) Grinding 100g of barnacle soft body part into powder in a grinder added with liquid nitrogen;
(2) Adding 500ml of distilled water, uniformly mixing, adjusting the pH value to 6.5, adding 10g of papain, and hydrolyzing at 60 ℃ for 4-6h;
(3) After the hydrolysis is finished, heating in water bath at 95 ℃ for 30 minutes, centrifuging and collecting supernatant to obtain barnacle enzymatic hydrolysate;
(4) Filtering the barnacle enzymatic hydrolysate by using a 5KDa ultrafiltration membrane, and collecting filtrate to obtain a barnacle peptide extracting solution;
(5) And (4) carrying out freeze drying on the barnacle peptide extracting solution to obtain the barnacle peptide.
Example 2
(1) The barnacle peptide is prepared into 50mg/ml,100mg/ml and 150mg/ml barnacle peptide reagent by using DMEM culture medium;
(2) 1X 10 of 100ul of logarithmic growth phase4HUVEC (human umbilical vein endothelial cells) in each ml in a 96-well culture plate, and placing in a cell culture box;
(3) After 1d of incubation, the medium was removed and the cells were washed 2 times with PBS, control: serum-free DMEM medium was added and treated for 24h, experimental group a: after the serum-free DMEM medium is treated for 4 hours, adding a serum-free medium containing 10 mu mol/L cholesterol to treat for 20 hours; experimental group B: adding 50mg/ml barnacin for treatment for 4h, and adding serum-free medium containing 10 μmol/L cholesterol for treatment for 20h; experimental group C: adding 100mg/ml barnacin for treatment for 4h, and adding serum-free medium containing 10 μmol/L cholesterol for treatment for 20h; experimental group D: adding 150mg/ml barnacin, treating for 4 hr, adding 10 μmol/L cholesterol-containing serum-free culture medium, treating for 20 hr, setting blank control, and setting 3 repeats per group;
(4) After the treatment is finished, adding an MTT reagent, and placing in a cell culture box for 4h;
(5) Removing supernatant, adding DMSO, and shaking in a shaking table in dark for 20min;
(6) The cells were placed in a microplate reader at 570nm for absorbance detection and cell viability was calculated, and the experimental results obtained are shown in FIG. 1.
From the figure, it can be seen that the cell viability of the experimental group a is 62.84 ± 2.84, the cell viability of the experimental group B is 73.12 ± 3.61, the cell viability of the experimental group C is 84.09 ± 3.10, and the cell viability of the experimental group D is 84.99 ± 3.12, and from the results, after the barnacin pretreatment, the HUVEC cell viability decrease caused by cholesterol can be effectively improved, and the difference has statistical significance.
Example 2
(1) 1 × 10 of logarithmic growth phase5The HUVEC (human umbilical vein endothelial cells) in each ml are placed in a 96-hole culture plate and are placed in a cell incubator for culture;
(2) When the cell density reached 90%, the medium was removed and the cells were washed 2 times with PBS, control: serum-free DMEM medium was added and treated for 24h, experimental group 1: after the serum-free DMEM medium is treated for 4 hours, adding a serum-free medium containing 10 mu mol/L cholesterol to treat for 20 hours; experimental group 2: adding 100mg/ml barnacin for treatment for 4h, and adding 10. Mu. Mol/L cholesterol-containing serum-free medium for treatment for 20h;
(3) After the treatment, the culture medium was removed, the cells in the 6-well plate were washed 3 times with PBS, and then 100ul of lysate was added to each well;
(4) Scraping the cells with a cell scraper, mixing the lysate and the cells thoroughly, and performing lysis on ice for 30min;
(5) After lysis for 30min, the mixture of cell debris and lysate was pipetted into a 2ml centrifuge tube;
(6) 12000g, centrifuging at 4 ℃ for 10min, removing supernatant, putting the supernatant into a new centrifuge tube, measuring the protein concentration, adding a protein loading buffer solution, and boiling the protein at 100 ℃ for 10min to obtain a protein sample;
(7) Installing an electrophoresis tank, carrying out protein sample loading, and adding a protein standard Marker into the first hole;
(8) Performing constant voltage electrophoresis by using 80V voltage, adjusting the voltage to 130V when the blue sample buffer solution reaches the separation gel, and stopping electrophoresis when the sample buffer solution reaches the bottom edge;
(9) Soaking a PVDF membrane in methanol for 1min, sequentially placing a sponge pad, filter paper, separation glue, a membrane, filter paper and the sponge pad from a cathode to an anode, clamping a rotating membrane clamp, placing the rotating membrane clamp into a membrane rotating groove, adding an ice box and a membrane rotating buffer solution, and then, performing 250mA constant current membrane rotation for 90min;
(10) After the membrane is transferred, taking out the PVDF membrane, washing the PVDF membrane for 3 times by using TBSR, preparing 5% skimmed milk powder by using TBST, putting the PVDF membrane into a confining liquid, and slightly oscillating and confining the PVDF membrane for 1 hour at room temperature;
(11) Rinsing the sealed membrane with TBST for 10min for 3 times, removing TBST, adding BAX, BCL-2 and beta-actin, and incubating at 4 deg.C overnight;
(12) After absorbing the primary antibody, rinsing with TBST for 3 times, 10min each time, adding the secondary antibody, and shaking gently for 1h at room temperature;
(13) The TBST rinse was performed 3 times, followed by chemiluminescence and development, and the results obtained are shown in fig. 2.
From the figure, it can be seen that in experimental group 1, the protein expression of the pro-apoptotic protein BAX was up-regulated, while the protein expression of the anti-apoptotic protein BCL-2 was down-regulated; in the experimental group 2, after the barnacin treatment, the up-regulation of protein expression of pro-apoptotic protein BAX and down-regulation of apoptosis-inhibiting protein BCL-2 caused by cholesterol are obviously reversed, which indicates that barnacin can effectively reverse the increase of HUVEC apoptosis caused by cholesterol.
Claims (2)
1. The application of the barnacin in preparing a biological agent for improving the reduction of the activity of endothelial cells of human umbilical veins caused by cholesterol is characterized in that the barnacin is prepared from barnacin soft body parts, and the preparation method for preparing the barnacin per 100g of the barnacin soft body parts comprises the following steps:
(1) Grinding 100g of barnacle soft body part into powder in a grinder added with liquid nitrogen;
(2) Adding 500ml of distilled water, mixing, adjusting pH to 6-7, adding 10g of papain, and hydrolyzing at 55-65 deg.C for 4-6h;
(3) After the hydrolysis is finished, heating in water bath at 90-95 ℃ for 20-30 minutes, centrifuging and collecting supernatant to obtain barnacle enzymatic hydrolysate;
(4) Filtering the barnacle enzymatic hydrolysate by using a 5KDa ultrafiltration membrane, and collecting filtrate to obtain a barnacle peptide extracting solution;
(5) And (3) carrying out freeze drying on the barnacle peptide extracting solution to obtain the barnacle peptide.
2. The application of the barnacin in preparing the biological agent for improving the increase of the apoptosis of endothelial cells of human umbilical veins caused by cholesterol is characterized in that the barnacin is prepared from barnacin soft body parts, and the preparation method for preparing the barnacin per 100g of the barnacin soft body parts comprises the following steps:
(1) Grinding 100g of barnacle soft body part into powder in a grinder added with liquid nitrogen;
(2) Adding 500ml of distilled water, mixing uniformly, adjusting the pH value to 6-7, adding 10g of papain, and hydrolyzing at 55-65 ℃ for 4-6h;
(3) After hydrolysis, heating in water bath at 90-95 ℃ for 20-30 minutes, centrifuging and collecting supernatant to obtain barnacle enzymatic hydrolysate;
(4) Filtering the barnacle enzymatic hydrolysate by using a 5KDa ultrafiltration membrane, and collecting filtrate to obtain a barnacle peptide extracting solution;
(5) And (3) carrying out freeze drying on the barnacle peptide extracting solution to obtain the barnacle peptide.
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211614887.4A CN115804827B (en) | 2022-03-18 | 2022-03-18 | Application of polypeptide in preparation of protective agent for reducing vascular endothelial function injury |
| CN202210267904.5A CN114404561B (en) | 2022-03-18 | 2022-03-18 | Protective agent for reducing vascular endothelial function damage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202210267904.5A CN114404561B (en) | 2022-03-18 | 2022-03-18 | Protective agent for reducing vascular endothelial function damage |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211614887.4A Division CN115804827B (en) | 2022-03-18 | 2022-03-18 | Application of polypeptide in preparation of protective agent for reducing vascular endothelial function injury |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN114404561A CN114404561A (en) | 2022-04-29 |
| CN114404561B true CN114404561B (en) | 2022-11-01 |
Family
ID=81263683
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202210267904.5A Active CN114404561B (en) | 2022-03-18 | 2022-03-18 | Protective agent for reducing vascular endothelial function damage |
| CN202211614887.4A Active CN115804827B (en) | 2022-03-18 | 2022-03-18 | Application of polypeptide in preparation of protective agent for reducing vascular endothelial function injury |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211614887.4A Active CN115804827B (en) | 2022-03-18 | 2022-03-18 | Application of polypeptide in preparation of protective agent for reducing vascular endothelial function injury |
Country Status (1)
| Country | Link |
|---|---|
| CN (2) | CN114404561B (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017043547A (en) * | 2015-08-24 | 2017-03-02 | 国立研究開発法人理化学研究所 | Polypeptide-binding growth factor and use thereof |
| CN112007058A (en) * | 2020-08-31 | 2020-12-01 | 广州中医药大学(广州中医药研究院) | Application of oroxylum indicum as antioxidant stress injury agent |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6310188B1 (en) * | 2000-01-24 | 2001-10-30 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Method for producing chitin or chitosan |
| US20030143673A1 (en) * | 2002-01-28 | 2003-07-31 | Kaplan David L. | Barnacle adhesion proteins |
| CN1678277B (en) * | 2002-07-29 | 2010-05-05 | 艾克里麦德公司 | Methods and compositions for treatment of dermal conditions |
| WO2009062975A1 (en) * | 2007-11-12 | 2009-05-22 | Cismi | Aerogel compositions |
| US8557297B2 (en) * | 2008-09-12 | 2013-10-15 | Olympic Seafood, As | Method for processing crustaceans and products thereof |
| CN113768947B (en) * | 2021-01-15 | 2023-05-02 | 青岛市第九人民医院 | Application of gene inhibitor in preparation of ischemic heart disease treatment medicine |
| CN112656947B (en) * | 2021-01-27 | 2022-07-01 | 青岛市中心医院 | Endothelial cell injury inhibitor |
-
2022
- 2022-03-18 CN CN202210267904.5A patent/CN114404561B/en active Active
- 2022-03-18 CN CN202211614887.4A patent/CN115804827B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2017043547A (en) * | 2015-08-24 | 2017-03-02 | 国立研究開発法人理化学研究所 | Polypeptide-binding growth factor and use thereof |
| CN112007058A (en) * | 2020-08-31 | 2020-12-01 | 广州中医药大学(广州中医药研究院) | Application of oroxylum indicum as antioxidant stress injury agent |
Non-Patent Citations (1)
| Title |
|---|
| 藤壶肽对吉富罗非鱼部分免疫指标的影响;胡文婷等;《饲料研究》;20150213(第01期);第51页第1.1节 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN114404561A (en) | 2022-04-29 |
| CN115804827B (en) | 2023-06-30 |
| CN115804827A (en) | 2023-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN106519020A (en) | Functional peptide with cosmetic efficacy and preparation method and application thereof | |
| CN109136174B (en) | Stem cell-derived exosome preparation for delaying senescence | |
| CN114404561B (en) | Protective agent for reducing vascular endothelial function damage | |
| CN114404441A (en) | Promoter for osteogenic differentiation of bone marrow mesenchymal stem cells | |
| SU1396958A3 (en) | Versions of method of producing derivatives of glicolipids stimulating regeneration of cells and tissue | |
| CN114606186A (en) | Method for improving proliferation of umbilical cord mesenchymal stem cells | |
| CN113151177B (en) | Breast or breast cancer tissue acellular matrix and preparation method and application thereof | |
| CN112877287B (en) | Application of bullacta exarata polypeptide in preparation of osteogenic differentiation accelerant for mesenchymal stem cells | |
| CN114836377B (en) | Stem cell in vitro osteogenic induction differentiation method | |
| CN104603616B (en) | Fine albumen 3 and/or sarcoglycan γ are used as the method for metrics evaluation cellulite and the method for evaluating cellulite active drug | |
| CN105648010A (en) | Preparation method of Sphyrna lewini meat antioxidative peptides capable of activating Nrf2-ARE pathway | |
| CN110151797B (en) | Application of sulfhydryl nitrosylation modification of tri-histidine nucleoside binding protein | |
| CN109464443B (en) | Novel application of Linifanib | |
| CN115350196B (en) | Biological preparation for reducing skin aging and improving skin injury repair | |
| CN113088549A (en) | Method for extracting antioxidant polypeptide from human placental blood | |
| CN114934089B (en) | Biological agent for lean pork pig breeding | |
| CN115010821B (en) | Application of polysaccharide in promoting growth of umbilical cord mesenchymal stem cells | |
| CN116036234B (en) | Medicament for treating osteoporosis | |
| CN117285597B (en) | Pentapeptide KK5 with uric acid reducing function and application thereof | |
| CN116650394A (en) | Stem cell anti-aging mask | |
| CN117210524A (en) | Antioxidant peptide in mutton and preparation method thereof | |
| CN114796258B (en) | Application of hucMSC-sEV loaded with miR13896 in sepsis acute liver injury | |
| CN112970743B (en) | Adipose-derived stem cell cryopreservation liquid and application thereof | |
| CN113817792A (en) | Application of marine biological polypeptide in preparation of medicine for treating osteoporosis | |
| CN117700487A (en) | Application of extracellular matrix protein in cosmetics for repairing skin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |